华氏巨球蛋白血症:2021年诊断、风险分层与管理更新
本文综述华氏巨球蛋白血症(WM)的诊断标准、风险分层及治疗管理更新。诊断依据IgM单克隆蛋白伴骨髓≥10%克隆性淋巴浆细胞,MYD88 L265P突变见于>90%患者。年龄、血红蛋白、血小板、β2微球蛋白、LDH和IgM浓度预测预后。无症状患者可观察,利妥昔单抗联合方案优于单药,复发可用硼替佐米等。
要点
- 诊断需IgM单克隆蛋白伴骨髓≥10%克隆性淋巴浆细胞。
- MYD88 L265P突变在>90%WM患者中可检测到。
- 无症状患者可观察,利妥昔单抗联合方案优于单药。
核心结论
- WM诊断基于IgM单克隆蛋白和骨髓≥10%克隆性淋巴浆细胞,MYD88 L265P突变常见。
- 风险分层基于年龄、血红蛋白、血小板、β2微球蛋白、LDH和IgM浓度。
- 无症状患者可观察,利妥昔单抗联合方案优于单药,复发有多种药物可选。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- MYD88 L265P突变在>90%WM患者中可检测到,也见于多数IgM MGUS患者。
- 年龄、血红蛋白水平、血小板计数、β2微球蛋白、LDH和单克隆IgM浓度可预测结局。
- 利妥昔单抗单药劣于联合苯达莫司汀、烷化剂、蛋白酶体抑制剂或依鲁替尼的方案。
- 嘌呤核苷类似物有活性但使用减少,Mayo Clinic首选诱导为利妥昔单抗联合苯达莫司汀。
关键数值与推荐
- 诊断标准:IgM单克隆蛋白伴骨髓≥10%克隆性淋巴浆细胞。
- MYD88 L265P突变检出率>90%。
- 风险因素:年龄、血红蛋白、血小板、β2微球蛋白、LDH、单克隆IgM浓度。
临床怎么用
- 无症状WM患者可观察直至出现症状。
- 治疗选择利妥昔单抗联合苯达莫司汀等方案,而非单药。
- 复发可选硼替佐米、氟达拉滨、沙利度胺、依维莫司、BTK抑制剂、卡非佐米、来那度胺和苯达莫司汀。
- 治疗选择需考虑减少毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. DIAGNOSIS: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients and is found in the majority of IgM MGUS patients. RISK STRATIFICATION: Age, hemoglobin level, platelet count, β2 microglobulin, LDH and monoclonal IgM concentrations are characteristics that are predictive of outcomes. RISK-ADAPTED THERAPY: Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab-monotherapy is inferior to regimens that combine it with bendamustine, an alkylating agent, a proteosome inhibitor, or ibrutinib. Purine nucleoside analogues are active but usage is declining in favor of less toxic alternatives. The preferred Mayo Clinic induction is rituximab and bendamustine. MANAGEMENT OF REFRACTORY DISEASE: Bortezomib, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, and bendamustine have all been shown to have activity in relapsed WM. Given WM's natural history, reduction of therapy toxicity is an important part of treatment selection.
引用
- Gertz MA. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021. PMID: 33368476. doi:10.1002/ajh.26082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。